Insider Selling: Sight Sciences, Inc. (NASDAQ:SGHT) CEO Sells $55,600.20 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CEO Paul Badawi sold 24,174 shares of the company’s stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $2.30, for a total transaction of $55,600.20. Following the transaction, the chief executive officer now owns 6,010,580 shares in the company, valued at $13,824,334. The trade was a 0.40 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Paul Badawi also recently made the following trade(s):

• On Thursday, January 16th, Paul Badawi sold 24,819 shares of Sight Sciences stock. The shares were sold at an average price of $2.92, for a total value of $72,471.48.

Sight Sciences Price Performance

NASDAQ:SGHT opened at $2.30 on Friday. The company has a 50 day moving average price of $2.67 and a 200-day moving average price of $3.84. Sight Sciences, Inc. has a 1-year low of $2.04 and a 1-year high of $8.45. The firm has a market cap of $118.07 million, a price-to-earnings ratio of -2.25 and a beta of 2.46. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.18 and a quick ratio of 9.74.

Sight Sciences (NASDAQ:SGHT) last released its quarterly earnings data on Wednesday, March 5th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01). Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. The firm had revenue of $19.07 million during the quarter, compared to analysts’ expectations of $18.98 million. During the same period in the previous year, the firm posted ($0.22) EPS. Equities research analysts forecast that Sight Sciences, Inc. will post -0.99 EPS for the current year.

Analyst Ratings Changes

Several research firms have weighed in on SGHT. Piper Sandler dropped their price target on Sight Sciences from $5.50 to $3.50 and set a “neutral” rating on the stock in a research note on Thursday, March 6th. Citigroup dropped their target price on Sight Sciences from $4.60 to $3.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. UBS Group decreased their price objective on shares of Sight Sciences from $5.50 to $5.00 and set a “buy” rating for the company in a research note on Monday, January 27th. Stifel Nicolaus cut their price objective on shares of Sight Sciences from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Thursday, March 6th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Sight Sciences in a report on Thursday, March 6th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Sight Sciences has a consensus rating of “Hold” and an average price target of $3.83.

Hedge Funds Weigh In On Sight Sciences

A number of large investors have recently bought and sold shares of the business. KCK LTD. purchased a new stake in shares of Sight Sciences in the fourth quarter valued at approximately $15,925,000. Long Focus Capital Management LLC grew its stake in Sight Sciences by 158.8% in the 4th quarter. Long Focus Capital Management LLC now owns 2,238,632 shares of the company’s stock valued at $8,149,000 after acquiring an additional 1,373,535 shares during the period. Prosight Management LP increased its holdings in Sight Sciences by 71.1% in the 4th quarter. Prosight Management LP now owns 908,847 shares of the company’s stock worth $3,308,000 after acquiring an additional 377,625 shares in the last quarter. Geode Capital Management LLC raised its position in Sight Sciences by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 792,860 shares of the company’s stock worth $2,887,000 after acquiring an additional 8,731 shares during the period. Finally, State Street Corp raised its position in Sight Sciences by 17.4% during the third quarter. State Street Corp now owns 646,776 shares of the company’s stock worth $4,075,000 after acquiring an additional 95,843 shares during the period. Institutional investors and hedge funds own 55.51% of the company’s stock.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.